Ganske spennende oppsett på denne nå.
Dip under tidligere low satt i april 2018. Presentasjon av data i morgen og salgsanbefaling fra investech, uten at dette har gitt noe nevneverdig utslag i volum til nedsiden enda.
Targeted Radiopharmaceuticals Summit - Munich, Germany
Jostein Dahle, the CSO in Nordic Nanovector will present results from preclinical studies with 212PB-NNV003, a novel Targeted Alpha Therapy comprising its proprietary CD37-specific antibody (NNV003) coupled with the alpha-particle generating radioisotope lead-212 (212Pb) in models of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) at the Targeted Radiopharmaceuticals Summit.
The presentation will take place at 13th June 09:30-10:00 CEST and is entitled: Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL)


…Ohh grasping…







